Intertumoral heterogeneity in patient-specific drug sensitivities in treatment-naïve glioblastoma

BACKGROUND: A major barrier to effective treatment of glioblastoma (GBM) is the large intertumoral heterogeneity at the genetic and cellular level. In early phase clinical trials, patient heterogeneity in response to therapy is commonly observed; however, how tumor heterogeneity is reflected in indi...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:BMC Cancer
Autori principali: Skaga, Erlend, Kulesskiy, Evgeny, Fayzullin, Artem, Sandberg, Cecilie J., Potdar, Swapnil, Kyttälä, Aija, Langmoen, Iver A., Laakso, Aki, Gaál-Paavola, Emília, Perola, Markus, Wennerberg, Krister, Vik-Mo, Einar O.
Natura: Artigo
Lingua:Inglês
Pubblicazione: BioMed Central 2019
Soggetti:
Research Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6593575/
https://ncbi.nlm.nih.gov/pubmed/31238897
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-019-5861-4
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi